Clinical Trials

As part of the development process, our investigational radioligand products are evaluated in clinical trials to find new and better ways to image and treat disease. These studies are sponsored by Advanced Accelerator Applications.

Investigational products tested in clinical trials may not be approved by regulatory authorities, or they may be approved for certain indications but being tested to determine if they are useful in other conditions. Patients should discuss their potential participation in such studies with their physician. The table below lists ongoing oncology clinical trials with our investigational drugs.

Please Select Compound

Please select disease state

Study number	Study name/Title	Phase
NCT05142696	A Safety Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients in Combination With Carboplatin, Etoposide and Tislelizumab	I
NCT05109728	A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent	I
NCT04838626	GuideView: Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection	III
NCT04838613	GuidePath: Study of Diagnostic Performance of [18F]CTT1057 in BCR (Biochemical Recurrence)	III
NCT04720157	PSMAddition: International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC	III
NCT04712721	Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.	I
NCT04711135	Netter-P: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs	II
NCT04689828	PSMAfore: 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer	III
NCT04597411	AcTION: A Phase I Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer and Extensive Skeletal Metastases	I
NCT03972488	Netter-2: Study to evaluate the efficacy and safety of Lutathera in patients with grade 2 and grade 3 advanced GEP-NET	III
NCT03872778	NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB* Lesion Uptake *Formerly known as NeoBOMB1	I/IIa
NCT03511664	VISION: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer	III
NCT03490838	PROter: 177Lu-PSMA-R2 in patients with positive progressive, metastatic, castration resistant prostate cancer	I/II
NCT03490032	PROfind: 68Ga-PSMA-R2 in patients with biochemical relapse and metastatic prostate cancer	I/II
NCT01578239	Netter-1: Study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumors	III

Clinical Trials

Work in progress